

Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

Market Report | 2026-01-15 | 489 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

<https://mnmimg.marketsandmarkets.com/Images/drug-discovery-technologies-market-img-overview.webp>

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period. The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America's leading position globally.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side - 70% and Demand Side- 30%

-□By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%

-□By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMERIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolveIT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

Key Benefits of Buying the Report

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

- Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

Table of Contents:

1□INTRODUCTION□	42
1.1□STUDY OBJECTIVES□	42
1.2□MARKET DEFINITION□	42
1.3□STUDY SCOPE□	42
1.3.1□MARKET SEGMENTATION AND REGIONS COVERED□	43
1.3.2□INCLUSIONS AND EXCLUSIONS□	44
1.3.3□YEARS CONSIDERED□	44
1.4□CURRENCY CONSIDERED□	45
1.5□STAKEHOLDERS□	45
1.6□SUMMARY OF CHANGES□	45
2□EXECUTIVE SUMMARY□	47
2.1□MARKET HIGHLIGHTS AND KEY INSIGHTS□	47
2.2□KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS□	48
2.3□DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET□	49
2.4□HIGH-GROWTH SEGMENTS□	50
2.5□REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST□	51
3□PREMIUM INSIGHTS□	53
3.1□NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT□	53
3.2□DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES□	54
3.3□DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%)□	55
4□MARKET OVERVIEW□	56
4.1□INTRODUCTION□	56
4.2□MARKET DYNAMICS□	56
4.2.1□DRIVERS□	57
4.2.1.1□Increasing adoption of advanced screening platforms□	57

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.2.1.2	Shift toward biologics and advanced therapeutic modalities	58
4.2.1.3	Transition from conventional two-dimensional cultures to three-dimensional models	58
4.2.1.4	Technological innovations in assay miniaturization and automation	59
4.2.2	RESTRAINTS	59
4.2.2.1	High up-front investment in instruments, automation, and data infrastructure	59
4.2.2.2	Shortage of skilled personnel	60
4.2.3	OPPORTUNITIES	60
4.2.3.1	Growing demand for in-silico-based discovery	60
4.2.3.2	Increasing need for specialized ADME/Toxicology testing	60
4.2.4	CHALLENGES	61
4.2.4.1	Assay reproducibility and standardization issues	61
4.3	UNMET NEEDS AND WHITE SPACES	61
4.4	INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES	62
4.5	STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS	62
5	INDUSTRY TRENDS	64
5.1	PORTER'S FIVE FORCES ANALYSIS	64
5.1.1	INTENSITY OF COMPETITIVE RIVALRY	65
5.1.2	BARGAINING POWER OF SUPPLIERS	65
5.1.3	BARGAINING POWER OF BUYERS	66
5.1.4	THREAT OF SUBSTITUTES	66
5.1.5	THREAT OF NEW ENTRANTS	66
5.2	MACROECONOMIC OUTLOOK	66
5.2.1	INTRODUCTION	66
5.2.2	GDP TRENDS AND FORECAST	66
5.2.3	R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY	67
5.2.4	R&D TRENDS IN GLOBAL PHARMA INDUSTRY	67
5.3	VALUE CHAIN ANALYSIS	68
5.4	ECOSYSTEM ANALYSIS	69
5.5	PRICING ANALYSIS	71
5.5.1	AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024	71
5.5.2	AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024	71
5.5.2.1	Average selling price of instruments, by key player, 2024	72
5.5.2.2	Average selling price of consumables, by key player, 2024	73
5.5.3	AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022-2024	73
5.5.4	AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024	74
5.6	TRADE ANALYSIS	75
5.6.1	IMPORT SCENARIO FOR HS CODE 3822.00	76
5.6.2	EXPORT SCENARIO FOR HS CODE 3822.00	76
5.6.3	IMPORT SCENARIO FOR HS CODE 9027.00	77
5.6.4	EXPORT SCENARIO FOR HS CODE 9027.00	78
5.7	KEY CONFERENCES AND EVENTS, 2025-2026	79
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	80
5.9	INVESTMENT AND FUNDING SCENARIO	80
5.10	CASE STUDY ANALYSIS	81
5.10.1	AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT	81

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.10.2	INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY	82
5.10.3	NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN	82
	?	
5.11	IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET	82
5.11.1	INTRODUCTION	82
5.11.2	KEY TARIFF RATES	82
5.11.3	PRICE IMPACT ANALYSIS	86
5.11.4	KEY IMPACT ON COUNTRIES/REGIONS	86
5.11.4.1	US	86
5.11.4.2	Europe	87
5.11.4.3	Asia Pacific	87
5.11.5	END-USE INDUSTRY IMPACT	87
5.11.5.1	Pharmaceutical and Biotechnology Companies	87
5.11.5.2	Academic and Research Institutes	88
5.11.5.3	Contract Research Organizations (CROs)	88
6	TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS	89
6.1	KEY EMERGING TECHNOLOGIES	89
6.1.1	HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION	89
6.1.2	AUTOMATED LIQUID HANDLING	89
6.2	ADJACENT TECHNOLOGIES	90
6.2.1	AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS	90
6.2.2	DISCOVERY INFORMATICS & LAB DIGITALIZATION	90
6.3	TECHNOLOGY/PRODUCT ROADMAP	91
6.4	PATENT ANALYSIS	91
6.4.1	METHODOLOGY	91
6.4.2	NUMBER OF PATENTS FILED	91
6.4.3	LIST OF KEY PATENTS	93
6.5	FUTURE APPLICATIONS	94
6.6	IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET	94
6.6.1	TOP USE CASES AND MARKET POTENTIAL	95
6.6.2	BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS	96
6.6.3	CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET	96
6.6.4	INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS	96
6.6.5	CLIENTS' READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET	97
7	SUSTAINABILITY AND REGULATORY LANDSCAPE	98
7.1	REGIONAL REGULATIONS AND COMPLIANCE	98
7.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	98
7.1.2	INDUSTRY STANDARDS	100
7.1.2.1	North America	101
7.1.2.1.1	US	101
7.1.2.1.2	Canada	101
7.1.2.2	Europe	101
7.1.2.2.1	UK	102
7.1.2.3	Asia Pacific	102
7.1.2.3.1	China	102

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.2.3.2 Japan 103
- 7.1.2.3.3 India 103
- 7.1.2.3.4 South Korea 103
- 7.1.2.3.5 Australia 104
- 7.1.2.3.6 Rest of Asia Pacific 104
- 7.2 SUSTAINABILITY INITIATIVES 104
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 105
- 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 105
- 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 107
- 8.1 DECISION-MAKING PROCESS 107
- 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 107
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
- 8.2.2 KEY BUYING CRITERIA, BY END USER 108
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 109
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109
- 9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 111
- 9.1 INTRODUCTION 112
- 9.2 REAGENTS & CONSUMABLES 112
- 9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH 112
- 9.3 INSTRUMENTS 116
- 9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET 116
- 9.4 BIOINFORMATICS TOOLS & SOFTWARE 119
- 9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET 119
- 10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY 123
- 10.1 INTRODUCTION 124
- 10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES 124
- 10.2.1 AUTOMATED LIQUID HANDLING 128
- 10.2.1.1 Increasing focus on precision, integration, and productivity to drive market 128
- 10.2.2 MICROPLATE-BASED HTS 132
- 10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D to fuel market 132
- 10.2.3 LAB-ON-A CHIP 135
- 10.2.3.1 Increasing demand for more predictive preclinical models to boost market 135
- 10.2.4 LABEL-FREE TECHNOLOGY 139
- 10.2.4.1 Real-time, label-free interaction to accelerate segment growth 139
- 10.3 NEXT-GENERATION SEQUENCING 142
- 10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET 142
- 10.4 POLYMERASE CHAIN REACTION 146
- 10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET 146
- 10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES 149
- 10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET 149
- 10.6 X-RAY CRYSTALLOGRAPHY 152
- 10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET 152
- 10.7 CHROMATOGRAPHY 156
- 10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH 156
- 10.8 MASS SPECTROMETRY 159
- 10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET 159

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.9	OTHER TECHNOLOGIES	163
11	DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS	167
11.1	INTRODUCTION	168
11.2	TARGET IDENTIFICATION	168
11.2.1	INCREASING CLINICAL DATA VOLUME TO BOOST MARKET	168
11.3	TARGET VALIDATION	172
11.3.1	INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH	172
11.4	HIT-TO-LEAD IDENTIFICATION	175
11.4.1	GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET	175
11.5	LEAD OPTIMIZATION	179
11.5.1	INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET	179
11.6	CANDIDATE VALIDATION	182
11.6.1	INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH	182
12	DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA	186
12.1	INTRODUCTION	187
12.2	ONCOLOGY	187
12.2.1	SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH	187
?		
12.3	INFECTIOUS DISEASES	191
12.3.1	RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET	191
12.4	CARDIOVASCULAR DISEASES	194
12.4.1	INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET	194
12.5	NEUROLOGICAL DISEASES	198
12.5.1	INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET	198
12.6	ENDOCRINE & METABOLIC DISORDERS	201
12.6.1	RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET	201
12.7	AUTOIMMUNE DISORDERS	205
12.7.1	WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET	205
12.8	OTHER THERAPEUTIC AREAS	208
13	DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER	212
13.1	INTRODUCTION	213
13.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	213
13.2.1	TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRIBUTE TO GROWTH	213
13.3	ACADEMIC & RESEARCH INSTITUTES	217
13.3.1	RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC-INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH	217
13.4	CONTRACT RESEARCH ORGANIZATIONS (CROs)	220
13.4.1	INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH	220
14	DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION	224
14.1	INTRODUCTION	225
14.2	NORTH AMERICA	225
14.2.1	US	230
14.2.1.1	Expanding network of cross-border partnerships and investments to expedite growth	230
14.2.2	CANADA	233
14.2.2.1	Increasing adoption of AI and open-science models to accelerate growth	233
14.3	EUROPE	237

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.3.1 GERMANY 241
 - 14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market 241
- 14.3.2 UK 244
 - 14.3.2.1 Increasing focus on next-generation computational platforms to promote growth 244
- 14.3.3 FRANCE 248
 - 14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market 248
- 14.3.4 ITALY 251
 - 14.3.4.1 Rising research funding to contribute to growth 251
- 14.3.5 SPAIN 255
 - 14.3.5.1 Well-established network of research centers and universities to boost market 255
- 14.3.6 REST OF EUROPE 258
- 14.4 ASIA PACIFIC 262
 - 14.4.1 CHINA 266
 - 14.4.1.1 Global partnerships to propel market 266
 - 14.4.2 JAPAN 270
 - 14.4.2.1 Rising integration of AI and international partnerships to favor growth 270
 - 14.4.3 INDIA 273
 - 14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth 273
 - 14.4.4 AUSTRALIA 277
 - 14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth 277
 - 14.4.5 SOUTH KOREA 280
 - 14.4.5.1 Favorable public policies to support growth 280
- 14.4.6 REST OF ASIA PACIFIC 284
- 14.5 LATIN AMERICA 287
 - 14.5.1 BRAZIL 291
 - 14.5.1.1 Public-private collaborations to bolster growth 291
 - 14.5.2 MEXICO 295
 - 14.5.2.1 Rising demand for AI-powered research to support growth 295
- 14.5.3 REST OF LATIN AMERICA 298
- 14.6 MIDDLE EAST 302
 - 14.6.1 GCC COUNTRIES 305
 - 14.6.1.1 Saudi Arabia 309
 - 14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market 309
 - 14.6.1.2 UAE 312
 - 14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth 312
 - 14.6.1.3 Rest of GCC countries 316
 - 14.6.2 REST OF MIDDLE EAST 319
- 14.7 AFRICA 323
 - 14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET 323
- 15 COMPETITIVE LANDSCAPE 327
 - 15.1 OVERVIEW 327
 - 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN 327
 - 15.3 REVENUE ANALYSIS 329
 - 15.4 MARKET SHARE ANALYSIS 329
 - 15.5 BRAND/PRODUCT COMPARISON 332

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.5.1	THERMO FISHER SCIENTIFIC INC.	333
15.5.2	MERCK KGAA	333
15.5.3	AGILENT TECHNOLOGIES, INC.	333
15.5.4	REVVITY	333
15.5.5	ILLUMINA, INC.	333
15.6	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	333
15.6.1	STARS	334
15.6.2	EMERGING LEADERS	334
15.6.3	PERVASIVE PLAYERS	334
15.6.4	PARTICIPANTS	334
15.6.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	336
15.6.5.1	Company footprint	336
15.6.5.2	Region footprint	337
15.6.5.3	Product footprint	338
15.6.5.4	Technology footprint	339
15.6.5.5	Process footprint	340
15.7	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	341
15.7.1	PROGRESSIVE COMPANIES	341
15.7.2	RESPONSIVE COMPANIES	341
15.7.3	DYNAMIC COMPANIES	341
15.7.4	STARTING BLOCKS	341
15.7.5	COMPETITIVE BENCHMARKING	343
15.7.5.1	Detailed list of key startups/SMEs	343
15.7.5.2	Competitive benchmarking of key startups/SMEs	344
15.8	COMPANY VALUATION AND FINANCIAL METRICS	345
15.9	COMPETITIVE SCENARIO	346
15.9.1	PRODUCT LAUNCHES	346
15.9.2	DEALS	347
15.9.3	EXPANSIONS	348
15.9.4	OTHER DEVELOPMENTS	348
16	COMPANY PROFILES	349
16.1	KEY PLAYERS	349
16.1.1	THERMO FISHER SCIENTIFIC INC.	349
16.1.1.1	Business overview	349
16.1.1.2	Products offered	350
16.1.1.3	Recent developments	353
16.1.1.3.1	Product launches	353
16.1.1.3.2	Deals	354
16.1.1.3.3	Expansions	354
16.1.1.4	MnM view	354
16.1.1.4.1	Key strengths/Right to win	354
16.1.1.4.2	Strategic choices	355
16.1.1.4.3	Weaknesses/Competitive threats	355
16.1.2	MERCK KGAA	356
16.1.2.1	Business overview	356
16.1.2.2	Products offered	357
16.1.2.3	Recent developments	358

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.2.3.1 Deals 358
- 16.1.2.3.2 Expansions 359
- 16.1.2.4 MnM view 359
- 16.1.2.4.1 Key strengths/Right to win 359
- 16.1.2.4.2 Strategic choices 359
- 16.1.2.4.3 Weaknesses/Competitive threats 359
- 16.1.3 AGILENT TECHNOLOGIES, INC. 360
- 16.1.3.1 Business overview 360
- 16.1.3.2 Products offered 361
- 16.1.3.3 Recent developments 363
- 16.1.3.3.1 Product launches 363
- 16.1.3.3.2 Expansions 364
- 16.1.3.4 MnM view 364
- 16.1.3.4.1 Key strengths/Right to win 364
- 16.1.3.4.2 Strategic choices 364
- 16.1.3.4.3 Weaknesses/Competitive threats 364
- 16.1.4 REVVITY 365
- 16.1.4.1 Business overview 365
- 16.1.4.2 Products offered 366
- 16.1.4.3 Recent developments 368
- 16.1.4.3.1 Product launches 368
- 16.1.4.3.2 Deals 368
- 16.1.4.3.3 Expansions 368
- 16.1.4.4 MnM view 369
- 16.1.4.4.1 Key strengths/Right to win 369
- 16.1.4.4.2 Strategic choices 369
- 16.1.4.4.3 Weaknesses/Competitive threats 369
- ?
- 16.1.5 ILLUMINA, INC. 370
- 16.1.5.1 Business overview 370
- 16.1.5.2 Products offered 371
- 16.1.5.3 Recent developments 372
- 16.1.5.3.1 Product launches 372
- 16.1.5.3.2 Deals 373
- 16.1.5.3.3 Expansions 373
- 16.1.5.3.4 Other developments 374
- 16.1.5.4 MnM view 374
- 16.1.5.4.1 Key strengths/Right to win 374
- 16.1.5.4.2 Strategic choices 374
- 16.1.5.4.3 Weaknesses/Competitive threats 374
- 16.1.6 DANAHER CORPORATION 375
- 16.1.6.1 Business overview 375
- 16.1.6.2 Products offered 376
- 16.1.6.3 Recent developments 380
- 16.1.6.3.1 Product launches 380
- 16.1.6.3.2 Deals 380
- 16.1.6.3.3 Expansions 381

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1.6.4	MnM view	381
16.1.6.4.1	Key strengths/Right to win	381
16.1.6.4.2	Strategic choices	381
16.1.6.4.3	Weaknesses/Competitive threats	381
16.1.7	F. HOFFMANN-LA ROCHE LTD	382
16.1.7.1	Business overview	382
16.1.7.2	Products offered	383
16.1.7.3	Recent developments	385
16.1.7.3.1	Product launches	385
16.1.7.3.2	Deals	385
16.1.7.3.3	Other developments	385
16.1.8	BRUKER	386
16.1.8.1	Business overview	386
16.1.8.2	Products offered	387
16.1.8.3	Recent developments	388
16.1.8.3.1	Product launches	388
16.1.8.3.2	Deals	389
16.1.8.3.3	Expansions	389
16.1.9	QIAGEN	390
16.1.9.1	Business overview	390
16.1.9.2	Products offered	391
16.1.9.3	Recent developments	392
16.1.9.3.1	Product launches	392
16.1.9.3.2	Deals	393
16.1.9.3.3	Expansions	393
16.1.10	BIO-RAD LABORATORIES, INC.	394
16.1.10.1	Business overview	394
16.1.10.2	Products offered	395
16.1.10.3	Recent developments	397
16.1.10.3.1	Product launches	397
16.1.10.3.2	Deals	397
16.1.11	TECAN TRADING AG	398
16.1.11.1	Business overview	398
16.1.11.2	Products offered	400
16.1.12	TAKARA BIO INC.	401
16.1.12.1	Business overview	401
16.1.12.2	Products offered	402
16.1.12.3	Recent developments	403
16.1.12.3.1	Product launches	403
16.1.13	CORNING INCORPORATED	404
16.1.13.1	Business overview	404
16.1.13.2	Products offered	406
16.1.14	HAMILTON COMPANY	407
16.1.14.1	Business overview	407
16.1.14.2	Products offered	407
16.1.14.3	Recent developments	408
16.1.14.3.1	Product launches	408

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.14.3.2 Deals 408
- 16.1.15 PACBIO 409
 - 16.1.15.1 Business overview 409
 - 16.1.15.2 Products offered 410
 - 16.1.15.3 Recent developments 412
 - 16.1.15.3.1 Product launches 412
 - 16.1.15.3.2 Expansions 412
- 16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC 413
 - 16.1.16.1 Business overview 413
 - 16.1.16.2 Products offered 415
 - 16.1.16.3 Recent developments 416
 - 16.1.16.3.1 Product launches 416
 - 16.1.16.3.2 Deals 416
- 16.1.17 PROMEGA CORPORATION 417
 - 16.1.17.1 Business overview 417
 - 16.1.17.2 Products offered 418
- ?
- 16.1.18 WATERS CORPORATION 419
 - 16.1.18.1 Business overview 419
 - 16.1.18.2 Products offered 421
 - 16.1.18.3 Recent developments 422
 - 16.1.18.3.1 Product launches 422
 - 16.1.18.3.2 Deals 422
- 16.1.19 SARTORIUS AG 423
 - 16.1.19.1 Business overview 423
 - 16.1.19.2 Products offered 425
 - 16.1.19.3 Recent developments 426
 - 16.1.19.3.1 Deals 426
- 16.1.20 BD 427
 - 16.1.20.1 Business overview 427
 - 16.1.20.2 Products offered 428
 - 16.1.20.3 Recent developments 429
 - 16.1.20.3.1 Product launches 429
 - 16.1.20.3.2 Deals 430
- 16.1.21 EPPENDORF SE 431
 - 16.1.21.1 Business overview 431
 - 16.1.21.2 Products offered 433
 - 16.1.21.3 Recent developments 434
 - 16.1.21.3.1 Deals 434
- 16.1.22 SHIMADZU CORPORATION 435
 - 16.1.22.1 Business overview 435
 - 16.1.22.2 Business overview 435
 - 16.1.22.3 Products offered 436
- 16.1.23 AURORA BIOMED INC. 438
 - 16.1.23.1 Business overview 438
 - 16.1.23.2 Products offered 438
- 16.1.24 STANDARD BIOTOOLS 439

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.24.1 Business overview 439
- 16.1.24.2 Products offered 440
- 16.1.25 EOL LTD. 441
 - 16.1.25.1 Business overview 441
 - 16.1.25.2 Products offered 443
- 16.1.26 GILSON INCORPORATED 444
 - 16.1.26.1 Business overview 444
 - 16.1.26.2 Products offered 444
- 16.1.27 BIOMERIEUX 445
 - 16.1.27.1 Business overview 445
 - 16.1.27.2 Products offered 446
- ?
- 16.1.28 GREINER AG 447
 - 16.1.28.1 Business overview 447
 - 16.1.28.2 Products offered 448
- 16.1.29 BGI GROUP 449
 - 16.1.29.1 Business overview 449
 - 16.1.29.2 Products offered 449
- 16.1.30 PORVAIR 451
 - 16.1.30.1 Business overview 451
 - 16.1.30.2 Products offered 452
- 16.2 OTHER PLAYERS 453
 - 16.2.1 POLARIS GENOMICS 453
 - 16.2.2 BICO 454
 - 16.2.3 CREATIVE BIOARRAY 455
 - 16.2.4 SPHERE BIO 455
 - 16.2.5 GENSCRIPT 456
 - 16.2.6 SCHRODINGER, INC. 457
 - 16.2.7 LECO CORPORATION 458
 - 16.2.8 TRANSGEN BIOTECH CO., LTD 459
 - 16.2.9 BMG LABTECH 460
 - 16.2.10 NANOTEMPER TECHNOLOGIES 461
 - 16.2.11 MGI TECH CO., LTD. 462
 - 16.2.12 ARACELI BIOSCIENCES 463
 - 16.2.13 ANALYTIK JENA GMBH+CO. KG 464
 - 16.2.14 BIOSOLVEIT GMBH 465
 - 16.2.15 EVOSEP 466
- 17 RESEARCH METHODOLOGY 467
 - 17.1 RESEARCH DATA 467
 - 17.1.1 SECONDARY DATA 468
 - 17.1.1.1 Key data from secondary sources 468
 - 17.1.2 PRIMARY DATA 469
 - 17.1.2.1 Key data from primary sources 469
 - 17.1.2.2 Key primary participants 469
 - 17.1.2.3 Breakdown of primary interviews 470
 - 17.1.2.4 Key industry insights 471
 - 17.2 MARKET SIZE ESTIMATION 472

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.2.1	BOTTOM-UP APPROACH	472
17.2.2	TOP-DOWN APPROACH	474
17.2.3	BASE NUMBER CALCULATION	475
17.3	GROWTH FORECAST MODEL	476
17.4	DATA TRIANGULATION	477
17.5	FACTOR ANALYSIS	478
17.6	RESEARCH ASSUMPTIONS	478
17.7	RESEARCH LIMITATIONS AND RISK ASSESSMENT	479
18	APPENDIX	481
18.1	DISCUSSION GUIDE	481
18.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	485
18.3	CUSTOMIZATION OPTIONS	487
18.4	RELATED REPORTS	487
18.5	AUTHOR DETAILS	488

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

Market Report | 2026-01-15 | 489 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com